Familial Amyloid Polyneuropathy Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Familial Amyloid Polyneuropathy Market Trends and Insights

Expansion of Disease-Modifying Therapy Approvals

The familial amyloid polyneuropathy market broadened between late 2024 and mid-2026 as several therapies reached key regulatory milestones. The FDA approved a supplemental new drug application for vutrisiran, marketed as AMVUTTRA, for ATTR-CM in March 2025. The approval made AMVUTTRA the first medicine approved for both hATTR-PN and ATTR-CM. It also enabled providers to serve both conditions through an established specialty pharmacy infrastructure. The European Commission approved eplontersen, marketed as WAINZUA, for Stage 1 and Stage 2 ATTRv-PN in March 2025. WAINZUA was the only EU-approved medicine for this indication that could be delivered through a monthly self-administered autoinjector at that time. The European Commission also granted marketing authorization for ATTROGY, diflunisal from Purpose Pharma, in July 2025 for adults with Stage 1 or Stage 2 polyneuropathy. The pivotal Phase 3 study showed an 18-point NIS+7 advantage over placebo at 24 months.

Growing RNA-Silencer Adoption

RNA-silencing medicines have become an important treatment mechanism in the familial amyloid polyneuropathy market. These medicines include small interfering RNAs and antisense oligonucleotides that reduce transthyretin production. Their use has reduced the central role once held by liver transplantation for suppressing transthyretin production. AMVUTTRA, a quarterly subcutaneous siRNA, generated USD 2.31 billion in 2025 global net product revenue. This represented a 138% increase from USD 970 million in 2024, following the March 2025 ATTR-CM approval. ONPATTRO revenue declined 32% to USD 172.8 million in 2025 as patients moved to the once-quarterly formulation^{[1]Alnylam Pharmaceuticals, Inc., “Alnylam Pharmaceuticals Reports Second Quarter 2026 Financial Results,” SEC EDGAR, sec.gov.}. Eplontersen generated USD 212 million in 2025 while its EU launch progressed, and an ATTR-CM application was expected in 2026. The shift toward quarterly and monthly dosing is moving care toward home-based administration and is changing distribution needs in the familial amyloid polyneuropathy market.

Earlier Genetic Testing and Multisystem Diagnosis

The diagnostic pathway for transthyretin-related amyloidosis is changing through hereditary amyloidosis next-generation sequencing panels and family-cascade programs. A 2025 study found that single-gene TTR testing had a 15.6% positivity rate in specialty genetics programs. The rate was more than 10 times higher than the result from broad neuropathy panels in the study population. This result supports targeted testing where clinical suspicion is high. Bone-avid radiotracer imaging with Tc-99m PYP, DPD, and HMDP can support biopsy-free cardiac ATTR diagnosis when AL amyloidosis is excluded. Genetic testing, neurological assessment, and cardiac imaging increasingly work as linked parts of the patient pathway. This approach can shorten the path to diagnosis and support treatment planning in the familial amyloid polyneuropathy market.

Family Cascade Testing and Specialist Care Capacity

The Val30Met variant creates concentrated family clusters in Portugal, Japan, Sweden, and Brazil. Northern Portugal had an estimated prevalence of 1 in 1,108 people, and penetrance reached 80% by age 50. Northern Sweden had 11% penetrance, with clinical onset often occurring later in life^{[2]Arquivos de Neuro-Psiquiatria, “Brazilian Consensus for Diagnosis, Management and Treatment of Hereditary Transthyretin Amyloidosis with Peripheral Neuropathy: Second Edition,” Arquivos de Neuro-Psiquiatria, scielo.br.}. Brazil had a penetrance of 83% by age 63, and the REACT-SP registry found that 51.1% of Brazilian ATTR patients carried the neurological phenotype. These clusters give specialist centers a practical basis for focused neurology-to-genetics referral pathways. A diagnosed index case can identify several first-degree relatives who may enter monitoring before symptoms appear. Specialist amyloidosis centers in endemic areas can coordinate testing, counseling, imaging, and treatment follow-up, which supports consistent access across the familial amyloid polyneuropathy market.

Ultra-High Treatment Cost and Reimbursement Friction

Treatment cost is a continuing limit on patient access in the familial amyloid polyneuropathy market. Annual list prices ranged from USD 244,000 for acoramidis at launch to USD 464,000 for vutrisiran. European health-technology assessment bodies have often linked reimbursement to post-marketing evidence obligations. This approach can leave diagnosed patients untreated while coverage decisions move through payer systems. It can also give payers greater influence over formulary placement and rebate rates when several branded medicines compete for the same patients. EU orphan-medicine rules and national pricing systems in Japan and Germany can support entry while also placing pressure on net revenue through the product lifecycle. Cost pressure is therefore likely to affect access patterns even where diagnostic capacity is improving.

Regulatory, Safety-Monitoring, and Vitamin A Management Requirements

RNA-silencing therapies that lower circulating transthyretin also lower retinol-binding protein. Patients, therefore, require daily vitamin A supplementation and periodic serum monitoring to reduce the risk of ocular complications. These requirements add coordination work for care teams, especially where dietitian and ophthalmology capacity is limited. In October 2025, Intellia Therapeutics reported a clinical hold on MAGNITUDE and MAGNITUDE-2 after a Grade 4 liver transaminase elevation^{[3]Amyloidosis Research Consortium, “ATTR Amyloidosis MAGNITUDE Clinical Trials Temporarily Paused,” Amyloidosis Research Consortium, arci.org.}. The FDA lifted the hold on MAGNITUDE-2 in January 2026 after Intellia agreed to enhanced liver laboratory monitoring and expanded enrollment to 60 patients. The action applied to MAGNITUDE-2 for ATTRv-PN rather than the full development program. Liver-safety evidence remains an important development requirement for gene-editing candidates in the familial amyloid polyneuropathy market.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Modality: Treatment Holds the Largest Position While Diagnosis Expands

Treatment accounted for 82.31% of the familial amyloid polyneuropathy market share in 2025. Disease-modifying transthyretin stabilizers and RNA silencers supported this position. TTR gene silencers have become a major source of growth within treatment. AMVUTTRA recorded USD 2.31 billion in 2025 net product revenue, while eplontersen recorded USD 212 million in its launch year. TTR stabilizers retain a substantial installed patient base. Clinical evidence indicates that gene-silencing approaches can reduce circulating transthyretin by 80% to 90%, while oral medicines provide partial stabilization. Prescribing may continue to move toward silencers among clinicians treating progressive polyneuropathy. Gene-editing therapies remained investigational in 2026, and MAGNITUDE-2 resumed enrollment after the FDA lifted its hold.

Diagnosis is forecast to grow at a 10.25% CAGR through 2031. The familial amyloid polyneuropathy market size for diagnosis is supported by reimbursement for hereditary amyloidosis sequencing panels and nuclear scintigraphy. Single-gene TTR sequencing has shown a 15.6% positivity rate in genetics-referred cohorts. This performance creates a reason to use targeted protocols in high-suspicion groups. Bone-avid radiotracer imaging can enable biopsy-free ATTR diagnosis when AL amyloidosis has been excluded. Tissue biopsy and amyloid subtyping remain relevant when imaging results are unclear or when immunohistochemistry is needed. Multisystem assessments that combine genetics and imaging can increase the number of services used in each diagnostic episode. This supports diagnostic revenue growth above the overall rate for the familial amyloid polyneuropathy market.

By Disease Stage: Stage 1 Leads While Presymptomatic Carriers Grow Fastest

Stage 1 patients represented 70.24% of the familial amyloid polyneuropathy market share in 2025. These patients can walk without assistance and form much of the evidence base for approved therapies. The HELIOS-A and NEURO-TTRansform studies enrolled predominantly Stage 1 patients. This gives clinicians a clearer basis for treatment selection in this cohort. Stage 2 and Stage 3 patients receive treatment, but fewer therapies have equally robust label support for their level of disease burden. This remains a gap for treatments that can show efficacy across a broader range of severity. Providers also need to address neurological and cardiac manifestations that may progress at different rates. The current evidence base keeps Stage 1 at the center of treated patient value in the familial amyloid polyneuropathy market.

Presymptomatic pathogenic TTR-variant carriers are forecast to grow at a 12.22% CAGR through 2031. Family-cascade testing in endemic areas identifies a group that can be monitored before clinical symptoms develop. A 2024 study reported that presymptomatic scintigraphic and genetic cascade screening identified subclinical cardiac ATTR in at-risk relatives before symptom onset. This provides clinical support for earlier treatment discussions. Annual monitoring of first-degree relatives at reference centers can create regular points for reassessment. Treatment decisions for these carriers will still depend on evidence, disease risk, and payer criteria. Their expansion could increase their share of new treatment starts by 2031. It could also reduce Stage 1's relative weight in the familial amyloid polyneuropathy market over time.

By Distribution Channel: Hospital Pharmacies Lead as Home Dosing Builds

Hospital pharmacies held 48.14% of the familial amyloid polyneuropathy market share in 2025. Their position reflects infusion-based patisiran use and the institutional services involved in treatment initiation and monitoring. Hospital settings also support specialist evaluation for patients with complex neurological and cardiac needs. The distribution mix is moving toward products that can be managed outside infusion centers. Quarterly subcutaneous vutrisiran reduces the frequency of administration visits. Monthly eplontersen uses an autoinjector format that supports self-administration. These formats can lower scheduling demands for patients and providers. They also increase the importance of specialty dispensing and patient education in the familial amyloid polyneuropathy market.

Online and digital fulfillment is forecast to grow at a 12.42% CAGR through 2031. The channel benefits from regular delivery needs for self-administered medicines and from services that help patients navigate coverage. Specialty pharmacy models can combine dispensing, benefits support, patient education, and care-team contact. PANTHERx opened a fulfillment center in Collierville, Tennessee, in September 2025 to add capacity and geographic redundancy for ultra-rare disease therapies. Retail pharmacies retain a more limited role for oral therapies such as tafamidis and acoramidis. Payer specialty requirements can still direct many ATTR-PN prescriptions to accredited providers. A potential one-time gene-editing infusion would require a different model centered on hospitals and infusion centers. The distribution balance in the familial amyloid polyneuropathy market will therefore depend on the treatment format that gains approval.

Geography Analysis

North America held 45.61% of the familial amyloid polyneuropathy market share in 2025. The United States has been the primary approval and launch location for major transthyretin-targeting medicines. The March 2025 FDA approval of vutrisiran for ATTR-CM expanded prescribing beyond neurology into cardiology. This added a larger patient group to specialty pharmacy systems already serving hATTR-PN. Canada and Mexico contribute smaller revenue shares. Their uptake is affected by formulary review schedules and specialist center availability in major metropolitan areas. North American competition also reflects the substantial commercial role of branded therapy.

Europe has concentrated endemic clusters in Portugal and Sweden and a developed clinical research base. Its adoption patterns vary because health-technology assessments and reimbursement decisions are made country by country. Eplontersen received European Commission approval for Stage 1 and Stage 2 ATTRv-PN in March 2025. Germany, France, Spain, Italy, and the United Kingdom remain major revenue pools for the familial amyloid polyneuropathy market. EU orphan-medicine designations can support access but are followed by price negotiations and evidence obligations. Portugal's approach to family monitoring supports earlier identification within endemic clusters. The region combines strong clinical capacity with uneven access to high-cost medicines.

Asia-Pacific is forecast to grow at an 11.25% CAGR through 2031. Japan's multidisciplinary care pathways coordinate genetic testing, neurological assessment, and cardiac imaging through regional referral networks. China's approval of eplontersen in 2025 expanded access to an RNA-silencing option in a large rare-disease population. South Korea and Australia have supporting conditions through RNAi research activity and an orphan-drug access pathway, respectively. Brazil also remains important because of its endemic Val30Met cluster. ANVISA approved BEYONTTRA, acoramidis, for ATTR-CM in Brazil in May 2026. BridgeBio planned commercialization with Biopas in the second half of 2026.